MUCOMMUNE, LLC
Carrboro, NC · Biotech · Private
monoclonal antibody (mAb) therapeutic formulation for dual contraception and HIV prevention delivered to the female reproductive tract
- Grants
- $23M
- 40 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Delivery of pathogen-trapping antibodies for vaginal protection | $222,725 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Delivery of pathogen trapping antibodies for vaginal protection | $272,725 | |
| Federal grant | Department of Health and Human Services · Phase I · Delivery of pathogen-trapping antibodies for vaginal protection | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Sustained vaginal delivery of monoclonal antibodies for preventing HIV transmission | $224,883 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a biologic for non-hormonal contraception | $212,994 | |
| Federal grant | Department of Health and Human Services · Phase I · Nebulized 'muco-trapping' antibodies for treating respiratory syncytial virus (RSV) infections | $224,893 | |
| Federal grant | Department of Health and Human Services · Phase II · Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | $224,934 | |
| Federal grant | Department of Health and Human Services · Phase I · Non-hormonal contraception based on vaginal delivery of multimeric sperm-binding antibodies | $224,728 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of RespiraClear for targeted mucosal treatment of RSV infections | $224,961 | |
| Federal grant | Department of Health and Human Services · Phase II · In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | $999,032 | |
| Federal grant | Department of Health and Human Services · Phase I · Aerosol immunotherapy for treatment of human metapneumovirus infection | $261,742 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhaled 'muco-trapping' antibody as universal immunotherapy for influenza virus infections | $275,437 | |
| Federal grant | Department of Health and Human Services · Phase II · In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring | $972,804 | |
| Federal grant | Department of Health and Human Services · Phase II · In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | $995,652 | |
| Federal grant | Department of Health and Human Services · Phase I · Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase II · SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | $1,702,035 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of RespiraClear for targeted mucosal treatment of RSV infections | $658,372 | |
| Federal grant | Department of Health and Human Services · Phase I · Multipurpose vaginal ring for non-hormonal contraception and preventing bacterial vaginosis | $265,970 | |
| Federal grant | Department of Health and Human Services · Phase II · In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring | $756,985 | |
| Federal grant | Department of Health and Human Services · Phase II · Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | $791,080 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of RespiraClear for targeted mucosal treatment of RSV infections | $891,585 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody | $277,713 | |
| Federal grant | Department of Health and Human Services · Phase I · Fast dissolving antibody tablets for preventing vaginal HSV transmission | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase I · User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring | $259,499 | |
| Federal grant | Department of Health and Human Services · Phase II · IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring | $1,039,122 | |
| Federal grant | Department of Health and Human Services · Phase II · SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | $1,036,484 | |
| Federal grant | Department of Health and Human Services · Phase I · Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis | $306,483 | |
| Federal grant | Department of Health and Human Services · Phase II · IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring | $1,028,445 | |
| Federal grant | Department of Health and Human Services · Phase I · IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody | $291,458 | |
| Federal grant | Department of Health and Human Services · Phase II · SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | $1,037,049 | |
| Federal grant | Department of Health and Human Services · Phase I · IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody | $291,458 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis | $1,025,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis | $310,136 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and evaluation of a pegloticase biobetter for sustained suppressionof fructose-induced obesity | $359,608 | |
| Federal grant | Department of Health and Human Services · Phase II · SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy | $1,031,566 | |
| Federal grant | Department of Health and Human Services · Phase II · Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception | $1,130,880 | |
| Federal grant | Department of Health and Human Services · Phase II · SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma | $1,146,618 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia | $409,732 | |
| Federal grant | Department of Health and Human Services · Phase II · IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis | $992,780 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2563 | Sentia Medical Sciences, Inc. | — | — |
| 2564 | Island Pharmaceuticals Ltd | — | $1.2M |
| 2565 | LactaLogics, Inc. | — | $1.1M |
| 2566 | MUCOMMUNE, LLC | — | — |
| 2567 | Ichor Microbial Solutions, Inc. | — | $1.1M |
| 2568 | WAYPATH PHARMA LLC | — | — |
| 2569 | SENEX BIOTECHNOLOGY, INC. | — | $1.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Synthetic Binding Agents For Limiting Permeation Through Mucusapplication
- Synthetic Binding Agents For Limiting Permeation Through Mucusapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.